Controlled release metformin formulations

  • US 8,475,841 B2
  • Filed: 03/21/2011
  • Issued: 07/02/2013
  • Est. Priority Date: 03/20/1998
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of treating a human diabetic patient with an oral solid sustained release tablet of metformin hydrochloride, comprising:

  • administering the sustained release tablet to the human diabetic patient once a day with or after the patient'"'"'s evening meal, wherein the sustained release tablet comprises (a) a homogeneous core;

    (b) optionally a seal coat surrounding the core and (c) a modified polymeric membrane surrounding the seal coat if present or the core if the seal coat is not present wherein;

    the core comprises;

    (a)(i) 75-95% metformin hydrochloride based upon the total weight of the core(a)(ii) 3-15% of a binder based upon the total weight of the core; and

    (a)(iii) a lubricant; and

    the modified polymeric membrane comprises;

    (c)(i) a polymer that controls or sustains the release of the metformin from the core;

    (c)(ii) a plasticizer selected from the group consisting of triacetin, acetylated monoglyceride, grape seed oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, and glycerlotributyrate;

    (c)(iii) a water soluble or enteric flux enhancing agent selected from the group consisting of sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol, propylene glycol, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers and mixtures thereof; and

    the metformin is released from the core by a passageway and/or pores in the modified polymeric membrane so that the oral solid sustained release tablet exhibits the following in vitro dissolution profile when tested in a USP Type 2 apparatus at 75 rpms in 900 ml of a pH 7.5 phosphate buffer and 37°

    C.;

    0-25% of the metformin is released after 2 hours;

    10-45% of the metformin is released after 4 hours;

    30-90% of the metformin is released after 8 hours;

    not less than 50% of the metformin is released after 12 hours;

    not less than 60% of the metformin is released after 16 hours and not less than 70% of the metformin is released after 20 hours.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×